DRUG SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Bright Minds Biosciences

Investors who lost money when DRUG shares sold off on the FDA's partial clinical hold for the planned Phase 2 BMB-101 epilepsy trial may have the right to seek recovery, even if they have already sold.

NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Shareholders of Bright Minds Biosciences (NASDAQ: DRUG) are holding losses after the stock sold off when the FDA placed the Company's planned Phase 2 BMB-101 epilepsy trial on partial clinical hold. If you bought DRUG shares and lost money, whether you still hold them or sold after the drop, you may have legal rights. Affected investors are encouraged to find out if their DRUG losses may be recoverable now. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.

In placing the hold, the FDA cited toxicity findings in mice. It also cited insufficient pharmacokinetic and juvenile-toxicity data to support enrolling pediatric patients in the planned trial for developmental and epileptic encephalopathies (DEE). Bright Minds stated that the hold applies only to the planned U.S. study and does not affect its other ongoing trials. The Company said it disagrees with the FDA's interpretation of the mouse findings and is awaiting the agency's full letter. It also acknowledged that additional data or studies may be required.

SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of Bright Minds shareholders. Your rights do not depend on still owning the stock. Eligibility turns on when you purchased and whether you lost money. There is no minimum loss and no upfront cost to have your DRUG losses reviewed.

DRUG shareholders who suffered losses are encouraged to request a review of their Bright Minds losses or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the DRUG Investigation

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Bright Minds Biosciences made materially false or misleading statements regarding BMB-101 and the data supporting its planned Phase 2 pediatric epilepsy trial. The stock price declined sharply when the Company disclosed that the FDA had placed the planned trial on partial clinical hold. The FDA cited mouse toxicity findings and insufficient pharmacokinetic and juvenile-toxicity data.

Q: When did Bright Minds Biosciences allegedly mislead investors?A: The investigation concerns statements made before the corrective disclosure that allegedly caused investors to purchase securities at inflated prices.

Q: What do DRUG investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my DRUG shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought DRUG and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: What if I live outside the United States?A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE SueWallSt.com